NCT06057922 2026-03-12
A Study YL201 in Patients With Selected Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2 Active not recruiting
Clinical Trials
14 trialsNCT05184712 2026-03-04
Phase 3 Clinical Study of AK112 for NSCLC Patients
Akeso
Phase 3 Active not recruiting
NCT05816252 2026-01-27
MK-2870-003
Klus Pharma Inc.
Phase 2 Active not recruiting
NCT04001777 2025-10-01
A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients
Ascentage Pharma Group Inc.
Phase 1 Active not recruiting
NCT06449027 2025-10-01
Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects.
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 3 Active not recruiting
NCT06385678 2025-09-19
A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2 Active not recruiting
NCT06198751 2025-08-19
A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Active not recruiting
NCT05906537 2025-08-07
SKB410 for Injection in Solid Tumors
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Phase 1 Active not recruiting
NCT05879627 2025-07-30
To Evaluate the Safety, Tolerance and Pharmacokinetics of BAT8007 for Injection in Patients With Advanced Solid Tumors
Bio-Thera Solutions
Phase 1 Active not recruiting
NCT06601504 2025-06-06
Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
Hutchmed
Phase 2 Active not recruiting
NCT05294172 2025-05-30
KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Phase 3 Active not recruiting
NCT06957379 2025-05-04
Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Active not recruiting
NCT04199689 2025-03-25
V503-049
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT05037149 2024-03-18
Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors
Sirnaomics
Phase 1 Active not recruiting